PERSEUS PROTEOMICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 344 JPY | -1.43% |
|
+14.67% | -44.34% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.34% | 26.72M | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -13.23% | 15.36B | |
| -8.82% | 11.95B | |
| -15.39% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- 4882 Stock
- News Perseus Proteomics Inc.
- Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera
